RxDoctor Payments Data

Sarat Pachalla, MD

Interventional Cardiology · Independence, MONPI 1346245024

Payments from drug & device makers

$6,807in general payments, 2019–2025

Across 400 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$950
  • Novartis$824
  • Johnson & Johnson$738
  • E.r. Squibb & Sons, L.L.C.$425
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$335
  • Boston Scientific$332
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$200%
  • Food & beverage$6,71199%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,807 in reported general payments places this provider in the 30th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$119,693
Medicare patients
652
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$283,825
XareltoRivaroxaban185$216,242
Repatha SureclickEvolocumab81$91,321
EntrestoSacubitril/Valsartan41$40,700
Repatha SyringeEvolocumab23$22,752
Praluent PenAlirocumab24$19,508
JardianceEmpagliflozin17$16,795
CorlanorIvabradine Hcl20$16,036
VascepaIcosapent Ethyl19$8,357
Ranolazine ErRanolazine31$6,445
Dabigatran EtexilateDabigatran Etexilate Mesylate13$6,058
Ezetimibe250$5,983
Atorvastatin Calcium454$3,923
Rosuvastatin Calcium185$3,661
Diltiazem 24hr Er (Cd)Diltiazem Hcl99$2,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$328$283,825234 claims
Johnson & JohnsonXarelto$738$216,242185 claims
NovartisEntresto$824$40,70041 claims
Boehringer IngelheimJardiance$281$16,79517 claims
AmgenCorlanor$950$16,03620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →